C2N Diagnostics receives $15M investment to advance its blood test for Alzheimer's disease

The biotechnology startup plans to use its funding to develop a second version of its blood test that aims to help diagnose Alzheimer's disease.

C2N Diagnostics receives $15M investment to advance its blood test for Alzheimer's disease

C2N stated that the funding came from the GHR Foundation. This foundation focuses on Alzheimer’s prevention and builds on a $20 million GHR investment in 2020. C2N will have Fred Miller, GHR Chief Operating Officer, and Managing Director for Biomedical Programmes, as a board observer.